These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 24016212)

  • 1. The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication.
    Rask-Andersen M; Masuram S; Schiöth HB
    Annu Rev Pharmacol Toxicol; 2014; 54():9-26. PubMed ID: 24016212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Therapeutic Target Database: an internet resource for the primary targets of approved, clinical trial and experimental drugs.
    Liu X; Zhu F; Ma X; Tao L; Zhang J; Yang S; Wei Y; Chen YZ
    Expert Opin Ther Targets; 2011 Aug; 15(8):903-12. PubMed ID: 21619487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translation of molecular pathways into clinical trials of neuroendocrine tumors.
    Pavel M
    Neuroendocrinology; 2013; 97(1):99-112. PubMed ID: 22508344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DrugPath: a database for academic investigators to match oncology molecular targets with drugs in development.
    Shah ED; Fisch BM; Arceci RJ; Buckley JD; Reaman GH; Sorensen PH; Triche TJ; Reynolds CP
    Cancer Chemother Pharmacol; 2014 May; 73(5):1089-93. PubMed ID: 24663501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug development for cancer chemoprevention: focus on molecular targets.
    Johnson KA; Brown PH
    Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solute carriers as drug targets: current use, clinical trials and prospective.
    Rask-Andersen M; Masuram S; Fredriksson R; Schiöth HB
    Mol Aspects Med; 2013; 34(2-3):702-10. PubMed ID: 23506903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide identification of structural variants in genes encoding drug targets: possible implications for individualized drug therapy.
    Rasmussen HB; Dahmcke CM
    Pharmacogenet Genomics; 2012 Jul; 22(7):471-83. PubMed ID: 22466257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical development of molecularly targeted agents in combination with radiation therapy: a pharmaceutical perspective.
    Ataman OU; Sambrook SJ; Wilks C; Lloyd A; Taylor AE; Wedge SR
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e447-54. PubMed ID: 22819210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
    Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in the exploitation of novel drug targets.
    Rask-Andersen M; Almén MS; Schiöth HB
    Nat Rev Drug Discov; 2011 Aug; 10(8):579-90. PubMed ID: 21804595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting cancer with small-molecular-weight kinase inhibitors.
    Fabbro D; Cowan-Jacob SW; Möbitz H; Martiny-Baron G
    Methods Mol Biol; 2012; 795():1-34. PubMed ID: 21960212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
    Ozkan EE
    Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategy for the development of novel anticancer drugs.
    Saijo N; Tamura T; Nishio K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects.
    Wong MS; Sidik SM; Mahmud R; Stanslas J
    Clin Exp Pharmacol Physiol; 2013 May; 40(5):307-19. PubMed ID: 23534409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
    Widmer N; Bardin C; Chatelut E; Paci A; Beijnen J; Levêque D; Veal G; Astier A
    Eur J Cancer; 2014 Aug; 50(12):2020-36. PubMed ID: 24928190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of new drug classification terms in textual resources.
    Kolárik C; Hofmann-Apitius M; Zimmermann M; Fluck J
    Bioinformatics; 2007 Jul; 23(13):i264-72. PubMed ID: 17646305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel molecular targets for the therapy of urothelial carcinoma.
    Jana BR; Galsky MD; Hahn NM; Milowsky MI; Sonpavde G
    Expert Opin Ther Targets; 2012 May; 16(5):499-513. PubMed ID: 22510032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.